Quantcast
Home > Quotes > MTNB

Matinas Biopharma Holdings, Inc. Common Stock (MTNB) Quote & Summary Data

MTNB 
$1
*  
0.03
2.91%
Get MTNB Alerts
*Delayed - data as of Apr. 23, 2019 11:01 ET  -  Find a broker to begin trading MTNB now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    MTNB Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
4.5
Today's High / Low
$ 1.0326 / $ 0.984
Share Volume
143,281
90 Day Avg. Daily Volume
1,063,335
Previous Close
$ 1.03
52 Week High / Low
$ 1.50 / $ 0.3237
Market Cap
142,937,626
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.29

Intraday Chart

Shares Traded

Share Volume:
143,281
90 Day Avg. Daily Volume:
1,063,335

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.15

Trading Range

The current last sale of $1 is 208.93% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.0326 $ 1.50
 Low: $ 0.984 $ 0.3237

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on creating value through (i) the streamlined development under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA of our lead product candidate, MAT9001, a highly purified, prescription-only omega-3 free fatty acid formulation specifically designed for the treatment of cardiovascular and metabolic conditions and (ii) the application of our lipid nano-crystal (LNC) platform delivery technology to solve complex challenges relating to the delivery of small molecules, gene therapies, vaccines, proteins and peptides. In general, the development timeline for a 505(b)(2) New Drug Application, or NDA, is shorter and less expensive than an NDA developed under Section 505(b)(1) for new chemical entities that have never been approved in the United States.  ... More ...  



Risk Grade

Where does MTNB fit in the risk graph?


Risk Grade Scale



Consensus Recommendation

Analyst Info